ad

TTK Healthcare Share Price Surges Up to 20% on 17 November 2026 as the Board Meets on 20 November to Consider a Bonus Issue of Preference Shares, With Rs 256 Crore of Brand Sale Cash and a Low Price to Earnings in Focus

TTK Healthcare Rs 1,054.95 (+14.44%, 10:56 AM, 17 Nov). Day high Rs 1,110.90 (+20%). Board meets 20 Nov. Brand sale cash Rs 256 crore. Q2 profit Rs 222.97 crore. P/E 4.7.


17 Nov 2026 • 10:59 am

TTK Healthcare Share Price Surges Up to 20% on 17 November 2026 as the Board Meets on 20 November to Consider a Bonus Issue of Preference Shares, With Rs 256 Crore of Brand Sale Cash and a Low Price to Earnings in Focus

Quick Answer

TTK Healthcare shares rose as much as 20% to Rs 1,110.90 on 17 November, and traded near Rs 1,055 at 10:56 AM, up about 14%, after the company said its board will meet on 20 November to consider a scheme to give equity shareholders bonus non-convertible redeemable preference shares. The filing does not give the ratio, tenure, payout or reason, so those details are unknown until the board decides. Investors are also watching the Rs 256 crore cash the company received from selling two brands to Wipro Enterprises. Any bonus would need further approvals, so it will not arrive quickly.

TTK Healthcare share price jumped as much as 20% on Tuesday 17 November 2026, touching Rs 1,110.90, and was trading at Rs 1,054.95 on the BSE at 10:56 AM, up 14.44% from Rs 921.80. The trigger was a filing dated 16 November that the board will meet on 20 November to consider a preference share bonus.

This article explains what the filing says and what it leaves out, how a preference share bonus differs from a regular bonus, the brand sale cash, the valuation and momentum readings, the second quarter profit and the risks. We keep facts, our own working and guesses clearly apart.

Click Here – Get Free Investment Predictions

Price Action at 10:56 AM on 17 November

Measure Figure at 10:56 AM
TTK Healthcare (NSE: TTKHLTCARE) Rs 1,052.55 on NSE, up 13.70%
BSE price Rs 1,054.95, up 14.44%
Previous close on NSE Rs 925.75
Open and day range Open Rs 1,067.65, high Rs 1,110.90, low Rs 1,025.00
Peak gain from previous close About 20.0% (our arithmetic)
NSE volume so far About 3.95 lakh shares
52-week range Rs 735.00 to Rs 1,247.00

An early report put the volume at about 1.81 lakh shares by 9:10 AM, roughly 8.4 times the average of 21,420 shares. The volume has since more than doubled, which is about 18.5 times that average (our arithmetic). The next filing or data release could change how TTKHLTCARE is read.

The stock gave back part of its opening spike, so the 20% headline is the intraday peak, not the current gain. Check the live quote before relying on any number. Many investors revisit TTK Healthcare bonus issue after the closing bell once final volumes are known.

What the Filing Says and What It Leaves Out

Item Detail
Filing date 16 November 2026, under Regulation 29 of the SEBI listing rules
Board meeting Friday 20 November 2026
Item on the agenda Scheme of Arrangement between the company and its equity shareholders
Legal route Section 230 of the Companies Act, 2013
What is proposed Bonus issue of non-convertible redeemable preference shares
Not disclosed Ratio, number and face value, tenure, redemption terms, any coupon, rationale and record date
Trading window Closed for designated persons from 16 to 22 November

A report notes that a scheme of this kind generally needs more approvals, such as from shareholders and the National Company Law Tribunal, before any bonus is issued. That means the actual issue would come well after 20 November. A calm review of TTK Healthcare bonus issue usually beats a rushed reaction to one headline.

Until the board meets, nobody outside the company knows the terms. The 20 November meeting only considers the scheme, and the board may approve it, change it or defer it. For TTK Healthcare stock, confirm each figure against the exchange filing before relying on it. For TTK Healthcare stock, confirm each figure against the exchange filing before relying on it.

How a Preference Share Bonus Differs From a Regular Bonus

Feature Regular bonus shares Bonus preference shares (as proposed)
What you receive Extra equity shares A separate redeemable preference security
Effect on equity share count Rises, and the price adjusts on the ex-date Not stated in the filing
Ownership and voting Same as existing equity Depends on terms not yet disclosed
Payout Only through later dividends Redemption and any coupon depend on the terms
Approvals Usually a board and shareholder resolution A court-supervised scheme under Section 230 here

Non-convertible means the preference shares cannot be turned into equity, and redeemable means the company can repay them on a set basis later. The terms of this scheme have not been published. No single data point settles the question on TTK Healthcare bonus issue. No single data point settles the question on TTK Healthcare bonus issue.

The company has not said why it wants this structure. Some investors read it as a way to return surplus cash, but that is a guess, not a statement from the filing. Past patterns behind TTKHLTCARE do not guarantee a repeat. Past patterns behind TTKHLTCARE do not guarantee a repeat.

Compare healthcare stocks on the Univest Screener

What the TTK Healthcare Share Price Says About Valuation and Momentum

Indicator Reading Context
Price to earnings 4.71 at the previous close Industry average 24.86
Price to book 0.97 at the previous close About 1.11 at the live price (our arithmetic)
Book value per share Rs 949.82 Trailing earnings per share Rs 195.71
Return on equity 5.39% Debt to equity 0.02
Dividend yield 1.08% Another screen shows 0.96%
14-day RSI 53.74 Neutral zone
50-day simple average Rs 1,015.14 Price is about 3.7% above
20-day exponential average Rs 964.80 Price is about 9.1% above

The price to earnings of 4.71 looks very low, but trailing earnings per share of Rs 195.71 is inflated by a one-off gain from the brand sale, explained below. On operating earnings the stock is not nearly as inexpensive as that ratio suggests (our reading). Broader market direction also influences TTK Healthcare shares on any given day.

Market value is about Rs 1,491 crore at the live price on a share count of about 1.41 crore (our arithmetic), against Rs 1,303 crore in the data feed at the previous close. On TTK Healthcare bonus issue, a fair view compares today's numbers with the previous quarter. On TTK Healthcare bonus issue, a fair view compares today's numbers with the previous quarter.

The Rs 256 Crore Brand Sale and the Cash on the Books

Item Detail
Buyer Wipro Enterprises, for the EVA and Good Home brands
Consideration Rs 256 crore plus GST, received in cash
Agreements signed 23 July 2026, completion reported in early September
Revenue of the two brands in FY26 Rs 148 crore, about 17% of company turnover
Net book value of assets sold Rs 0.70 crore (as of 30 June 2026)
Cash as a share of market value About 17% at the live price (our arithmetic, before tax)
Cash per share About Rs 181 (our arithmetic, before tax and GST)

The price works out to about 1.7 times the brands' annual revenue. The company has not said how it will use the cash, and the filing for the board meeting does not link the cash to the scheme. Comparing TTK Healthcare shares with peers gives a better sense of context.

Taxes on the sale will reduce what is left for shareholders, so treat the per-share figure as a ceiling. Human pharma was sold earlier in May 2022, and the remaining business covers consumer brands, medical devices, animal health and foods. With TTKHLTCARE, position size matters more than precision. With TTKHLTCARE, position size matters more than precision.

Second Quarter Profit and Why It Needs Context

Measure Q2 FY27 Comparison
Standalone revenue Rs 233.38 crore Up 14.64% from Rs 203.57 crore
Operating profit Rs 3.75 crore EBITDA margin about 1.6%, down from 2.62%
Net profit Rs 222.97 crore Up about 994% from Rs 20.39 crore
Q1 FY27 net profit Rs 21.30 crore Up 63.85%, revenue Rs 260 crore

Operating profit was only Rs 3.75 crore, while net profit was Rs 222.97 crore. The gap very likely comes from the gain on the brand sale, though we have not seen the exceptional item line itself, so confirm it in the filing. Reading TTKHLTCARE alongside the sector trend avoids a narrow conclusion.

Without that gain, the quarter shows modest revenue growth and thinner margins. That is why the headline profit jump is a poor guide to the business's regular earning power. Volume is a useful cross-check for TTK Healthcare shares. Volume is a useful cross-check for TTK Healthcare shares.

Risks and What to Watch Next

Risk Why it matters
Unknown terms The ratio, tenure and payout are not public until the board decides
Long approval path Shareholder and tribunal approvals can take months
Board outcome The board can approve, change or defer the scheme
One-off earnings A low price to earnings rests on a sale gain, not repeat profit
Thin liquidity The average volume is only about 21,000 shares, so prices can swing sharply

Watch the outcome of the 20 November meeting, the exact terms in the exchange filing and any record date. A trading window closure until 22 November also limits purchases by company insiders. Set risk limits before acting on any view of TTK Healthcare stock.

Univest does not give buy or sell calls, and this article is general information. Size any position to your own risk limits. Updates related to TTK Healthcare stock often arrive after market hours, so check again at the next open. Updates related to TTK Healthcare stock often arrive after market hours, so check again at the next open.

Download the Univest iOS App or Univest Android App to track this stock and set price alerts.

Conclusion

The stock jumped on a short filing that names a preference share bonus but gives no terms. The board meets on 20 November, and any issue would need further approvals after that. When reading TTK Healthcare shares, intraday moves can reverse before the close, so timing matters. When reading TTK Healthcare shares, intraday moves can reverse before the close, so timing matters.

A low price to earnings and Rs 256 crore of sale cash support interest, yet the profit jump comes from a one-off gain and operating margins are thin. Wait for the actual terms before forming a view. Note the date and time of any price quoted in TTK Healthcare stock.

Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).

Frequently Asked Questions

Why did TTK Healthcare shares jump on 17 November 2026?

Ans. The company told the exchanges on 16 November that its board will meet on 20 November to consider a scheme to issue non-convertible redeemable preference shares as a bonus to equity shareholders. The stock rose as much as 20% to Rs 1,110.90 on the news.

What are bonus non-convertible redeemable preference shares?

Ans. They are preference shares given free to existing equity holders. They cannot be converted into equity, and the company can redeem them later on set terms. The ratio, tenure and any coupon for this scheme have not been disclosed yet.

When will the bonus be issued?

Ans. Not soon. The board only considers the scheme on 20 November 2026. A scheme under Section 230 generally needs shareholder and National Company Law Tribunal approvals, so any issue and record date would follow those steps and could take months.

Is TTK Healthcare really trading at a price to earnings of 4.7?

Ans. The data feed shows 4.71 at the previous close against an industry figure of 24.86. However, trailing earnings are inflated by the gain on selling the EVA and Good Home brands, so the ratio flatters the company. Regular operating profit is much lower.

How much did TTK Healthcare get from selling its brands?

Ans. It received Rs 256 crore plus GST in cash from Wipro Enterprises for the EVA and Good Home brands. The brands earned Rs 148 crore of revenue in FY26, about 17% of turnover. The company has not said how it will use the cash.

What happened in the second quarter results?

Ans. Standalone revenue was Rs 233.38 crore, up 14.64%, and net profit was Rs 222.97 crore against Rs 20.39 crore a year earlier. Operating profit was just Rs 3.75 crore, so the profit jump very likely reflects the brand sale gain.

Should I buy the stock before the board meeting?

Ans. Univest does not give buy or sell calls. The terms are unknown, the approval path is long and trading volume is thin, so prices can reverse quickly. Review the filing after 20 November and set your own risk limits first.

Recent Articles

Note: This blog is for information purpose only. Investments and trading are subject to market risks, read all scheme related documents carefully.

Reviews

user-review-1
user-review-2
user-review-3
user-review-4
user-review-5

RESEARCH ANALYST

Get SEBI Registered
advice on the stocks
trending today.

Get 3 FREE Trade Ideas

+91
for Startups Accelerator 2024

for Startups Accelerator 2024

Trusted by 1Cr Indians

Trusted by 1Cr Indians

Awarded No.1 by Economic Times

Awarded No.1 by Economic Times

GET THE APP

Join 1Cr users today.

SEBI Registered Analyst-backed Picks. Free Demat. One App

  • Free Demat account in under 5 minutes
  • Live market data — Nifty, Sensex, sector insights
  • SEBI Registered analyst-backed stock picks
Get it on Google PlayDownload on the App Store
Stocks:
All|a|b|c|d|e|f|g|h|i|j|k|l|m|n|o|p|q|r|s|t|u|v|w|x|y|z

Copyright 2026 Univest. All rights reserved.
Designed with ❤️ in India

arrow down